Related Experiment Video
Updated: Oct 21, 2025
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Mesenchymal stem cell therapy for severe COVID-19
Lei Shi1, Lifeng Wang1, Ruonan Xu1
1Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, 100039, Beijing, China.
Insights
Mesenchymal stem cell (MSC) therapy shows promise for treating severe COVID-19 by reducing lung damage and improving patient recovery. Clinical trials indicate MSCs offer safety and immune tolerance for coronavirus disease 2019 patients.
Area of Science:
- Immunology
- Regenerative Medicine
- Infectious Diseases
Background:
- Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, presents a significant global health challenge with no specific treatments.
- Severe COVID-19 can cause immune dysregulation and damage to both innate and adaptive immune responses, leading to lung injury.
Purpose of the Study:
- To review the current progress of mesenchymal stem cell (MSC) therapy for COVID-19.
- To highlight the therapeutic potential of MSCs in managing immune disorders and lung damage associated with SARS-CoV-2 infection.
Main Methods:
- Summary of findings from clinical trials investigating MSC therapy in COVID-19 patients.
- Review of the immunomodulatory and regenerative properties of MSCs relevant to COVID-19.
Main Results:
- MSC treatment has demonstrated significant reduction in lung damage in COVID-19 patients.
- MSC therapy has shown to improve patient recovery, exhibiting safety and good immune tolerance.
Conclusions:
- Mesenchymal stem cells represent a viable therapeutic strategy for severe COVID-19.
- Further research and clinical application of MSC therapy are warranted to address challenges in treating SARS-CoV-2-induced complications.
Abstract:
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a global public burden on health authorities. Although the virological characteristics and pathogenesis of COVID-19 has been largely clarified, there is currently no specific therapeutic measure. In severe cases, acute SARS-CoV-2 infection leads to immune disorders and damage to both the adaptive and innate immune responses. Having roles in immune regulation and regeneration, mesenchymal stem cells (MSCs) serving as a therapeutic option may regulate the over-activated inflammatory response and promote recovery of lung damage. Since the outbreak of the COVID-19 pandemic, a series of MSC-therapy clinical trials has been conducted. The findings indicate that MSC treatment not only significantly reduces lung damage, but also improves patient recovery with safety and good immune tolerance. Herein, we summarize the recent progress in MSC therapy for COVID-19 and highlight the challenges in the field.
More Related Videos
04:09Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
11:22Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
Published on: May 21, 2013
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...